U.K. Investor Group Petition: 3M Dropped The Ball On BacLite
This article was originally published in The Gray Sheet
Executive Summary
Over four years ago, 3M acquired U.K.-based startup Acolyte Biomedica and its BacLite technology to detect the antibiotic-resistant MRSA bacteria, with stated plans to conduct U.S. clinical trials and seek a 2008 U.S. market launch.
You may also be interested in...
3M Beams Into Clinical Diagnostics With Acolyte Biomedica Acquisition
3M entered the clinical diagnostics market Feb. 14 with its acquisition of U.K.-based Acolyte Biomedica and the BacLite system for detecting hospital-associated infectious diseases
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.